港股異動 | 白雲山AH股齊漲 子公司獲36個藥品再註冊批件
格隆匯12月31日丨白雲山(0874.HK)現報26.4港元,漲4.76%,暫成交4317萬港元,最新H股總市值429億港元。A股市場白雲山(600332.SH)現報35.24元,漲4.63%,暫成交5.3億元,最新A股總市值572.9億元。白雲山上週五(27日)晚間發公告稱,公司控股子公司廣州白雲山星羣(藥業)股份有限公司、公司全資子公司廣州白雲山奇星藥業有限公司和廣州白雲山中一藥業有限公司於近日收到廣東省藥監局核准簽發的關於華佗再造丸、消渴丸和滋腎育胎丸等36個藥品的《藥品再註冊批件》。此外據悉,第二批國家組織藥品集中採購和使用近日正式啟動,33個品種涉及百家藥企,花旗曾發研報推薦長期投資者買入優質藥企和生物科技企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.